

Medical Coverage Policy | Autologous Chondrocyte Implantation



EFFECTIVE DATE: 11|21|2003

POLICY LAST UPDATED: 05|07|2013

OVERVIEW

A variety of procedures are being developed to resurface articular cartilage defects. Autologous chondrocyte implantation (ACI) involves harvesting chondrocytes from healthy tissue, expanding the cells in vitro, and implanting the expanded cells into the chondral defect under a periosteal or fibrin patch. Second- and third-generation techniques include combinations of autologous or allogeneic chondrocytes, minced cartilage, scaffolds, and growth factors.

PRIOR AUTHORIZATION

Preauthorization is required for BlueCHiP for Medicare members and recommended for all other product lines.

POLICY STATEMENT

Autologous chondrocyte transplantation for the treatment of cartilage defects of the knee is **considered medically necessary** when the medical criteria below are met.

There is no scientific literature to support the use of Autologous chondrocyte implantation for all other joints, including patellar and talar or any indications other than those listed above, therefore all other indications are considered **not medically necessary**.

MEDICAL CRITERIA

Autologous chondrocyte implantation may be considered **medically necessary** for the treatment of disabling full-thickness articular cartilage defects of the knee caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior surgical procedure, when all of the following criteria are met:

- Adolescent patients should be skeletally mature with documented closure of growth plates (e.g., 15 years or older). Adult patients should be too young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (e.g., younger than 55 years)
- Focal, full-thickness (grade III or IV) unipolar lesions on the weight bearing surface of the femoral condyles or trochlea at least 1.5 cm² in size
- Documented minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge Grade II or less), and normal-appearing hyaline cartilage surrounding the border of the defect
- Normal knee biomechanics, or alignment and stability achieved concurrently with autologous chondrocyte implantation
- Absence of meniscal pathology

BACKGROUND

Damaged articular cartilage typically fails to heal on its own and can be associated with pain, loss of function, and disability and may lead to debilitating osteoarthritis over time. These manifestations can severely impair an individual's activities of daily living and adversely affect quality of life. Conventional treatment options include debridement, subchondral drilling, microfracture, and abrasion arthroplasty. Debridement involves

the removal of synovial membrane, osteophytes, loose articular debris, and diseased cartilage and is capable of producing symptomatic relief. Subchondral drilling, microfracture, and abrasion arthroplasty attempt to restore the articular surface by inducing the growth of fibrocartilage into the chondral defect. Compared to the original hyaline cartilage, fibrocartilage has less capability to withstand shock or shearing force and can degenerate over time, often resulting in the return of clinical symptoms. Osteochondral grafts and ACI attempt to regenerate hyaline-like cartilage and thereby restore durable function.

With autologous chondrocyte implantation, a region of healthy articular cartilage is identified and biopsied through arthroscopy. The tissue is sent to a facility licensed by the U.S. Food and Drug Administration (FDA) where it is minced and enzymatically digested, and the chondrocytes are separated by filtration. The isolated chondrocytes are cultured for 11–21 days to expand the cell population, tested, and then shipped back for implantation. With the patient under general anesthesia, an arthrotomy is performed, and the chondral lesion is excised up to the normal surrounding cartilage. A periosteal flap is removed from the proximal medial tibia and sutured to the surrounding rim of normal cartilage. The cultured chondrocytes are then injected beneath the periosteal flap.

The entire autologous chondrocyte implantation (ACI) procedure consists of 4 steps: 1) the initial arthroscopy and biopsy of normal cartilage, 2) culturing of chondrocytes, 3) a separate arthrotomy to create a periosteal flap and implant the chondrocytes, and 4) post-surgical rehabilitation. The initial arthroscopy may be scheduled as a diagnostic procedure; as part of this procedure, a cartilage defect may be identified, prompting biopsy of normal cartilage in anticipation of a possible chondrocyte transplant. The biopsied material is then sent for culturing and returned to the hospital when the implantation procedure (i.e., arthrotomy) is scheduled.

Although long-term studies are lacking, evidence indicates that ACI can improve symptoms in some patients with lesions of the articular cartilage of the knee who have failed prior surgical treatment. These patients, who are too young for total knee replacement, have limited options. Therefore, based on the clinical input, highly suggestive evidence from randomized controlled trials and prospective observational studies, it is concluded that ACI may be considered an option for the FDA-approved indication of disabling full-thickness chondral lesions of the femoral condyles or trochlea caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior procedure.

Additional studies are needed to evaluate whether marrow stimulation at the time of biopsy affects implant success. Recent evidence indicates that ACI combined with meniscal allograft results in outcomes similar to either procedure performed alone; therefore, combined procedures may be considered medically necessary.

Evidence is currently insufficient to evaluate the efficacy of ACI in comparison with other surgical repair procedures as a primary treatment of large lesions or to evaluate the efficacy of ACI for the patella or for joints other than the knee, therefore, this is considered not medically necessary.

Results from second generation ACI procedures (MACI) from Europe appear promising. These products use a variety of biodegradable scaffolds and have the potential to improve consistent hyaline cartilage formation and reduce complications associated with injection under a periosteal patch. To date no MACI products are approved in the U.S.; therefore, these are considered investigational. Minced cartilage techniques are in the early stages of development and testing and/or not approved in the U.S.; these are considered not medically necessary as there is no proven efficacy.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement, or Benefit Booklet for the applicable surgery benefits/coverage.

CODING

The following codes are covered when preauthorization has been obtained

27412

HCPCS supply code:

J7330

RELATED POLICIES

Not applicable.

PUBLISHED

Provider Update	Jul 2013
Provider Update	May 2012
Provider Update	Jul 2011
Provider Update	Sep 2009
Provider Update	Oct 2008
Policy Update	Jan 2007

REFERENCES

Blue Cross Blue Shield Association Medical Policy Reference. Policy 7.01.48 - Autologous Chondrocyte Implantation. Reviewed with literature search/November 2008.

Brown University: Autologous Chondrocyte Implantation (ACI):How It Works. Retrieved on May 21, 2009:http://biomed.brown.edu/Courses/BI108/BI108_1999_Groups/Cartilage_Team/christine/HowitWorks.html.

Carticel. Results from The Study of the Treatment of Articular Repair (STAR). Retrieved on May 21, 2009: <http://www.carticel.com/healthcare/about/star-study-research.aspx>.

National Institute for Health and Clinical Excellence (NICE). *Autologous chondrocyte implantation (ACI) for treating cartilage damage in the knee. Understanding NICE guidance - information for people with cartilage damage in the knee, their families and carers, and the public*. NICE;May 2005. Retrieved on May 20, 2009: <http://www.nice.org.uk/nicemedia/pdf/TA089guidance.pdf>.

National Institute for Health and Clinical Excellence (NICE). *Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints; technology assessment report*. NICE;August 2004.9). Retrieved on May 20, 2009: National Institute for Clinical Excellence (NICE) Web site.

National Institute for Health and Clinical Excellence (NICE) Quick reference guide. *The use of autologous chondrocyte implantation (ACI) for the treatment of cartilage defects in knee joints*. . NICE ;May 2008:2 p. Retrieved on May 20, 2009: National Institute for Clinical Excellence (NICE) Web site.

Ossendorf C, Kaps C, Kreuz C, et al. *Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results*. *Arthritis Research & Therapy*;2007;9(2):R41.

U.S. Food and Drug Administration (FDA). Center for biologics evaluation and research. Product approval information, autologous cultured chondrocytes (Carticel). (Package insert revision). FDA;June 21, 2007. Retrieved on May 20, 2009: <http://www.fda.gov/cber/products/carticel.htm>.

National Institute for Health and Clinical Excellence. The use of autologous chondrocyte implantation for the treatment of cartilage defects in knee joints. *Technology Appraisal Guidance No. 89* 2005. Available online at: <http://www.nice.org.uk/page.aspx?o=TA089guidance>.

American Academy of Orthopaedic Surgeons. Clinical practice guideline on the diagnosis and treatment of osteochondritis dissecans. 2010. Available online at: http://www.aaos.org/research/guidelines/OCD_guideline.pdf

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

